216 related articles for article (PubMed ID: 34156985)
1. KRAS-driven model of Gorham-Stout disease effectively treated with trametinib.
Homayun-Sepehr N; McCarter AL; Helaers R; Galant C; Boon LM; Brouillard P; Vikkula M; Dellinger MT
JCI Insight; 2021 Aug; 6(15):. PubMed ID: 34156985
[TBL] [Abstract][Full Text] [Related]
2. Trametinib inhibits lymphatic vessel invasion of bone in a mouse model of Gorham-Stout disease.
McCarter AL; Dellinger MT
J Vasc Anom (Phila); 2023 Dec; 4(4):. PubMed ID: 38737531
[TBL] [Abstract][Full Text] [Related]
3. A somatic activating KRAS variant identified in an affected lesion of a patient with Gorham-Stout disease.
Nozawa A; Ozeki M; Niihori T; Suzui N; Miyazaki T; Aoki Y
J Hum Genet; 2020 Nov; 65(11):995-1001. PubMed ID: 32591603
[TBL] [Abstract][Full Text] [Related]
4. Hyperactive KRAS/MAPK signaling disrupts normal lymphatic vessel architecture and function.
Fernandes LM; Tresemer J; Zhang J; Rios JJ; Scallan JP; Dellinger MT
Front Cell Dev Biol; 2023; 11():1276333. PubMed ID: 37842094
[TBL] [Abstract][Full Text] [Related]
5. Low‑dose trametinib and Bcl‑xL antagonist have a specific antitumor effect in KRAS‑mutated colorectal cancer cells.
Koyama M; Kitazawa M; Nakamura S; Matsumura T; Miyazaki S; Miyagawa Y; Muranaka F; Tokumaru S; Okumura M; Yamamoto Y; Ehara T; Hondo N; Takahata S; Takeoka M; Miyagawa SI; Soejima Y
Int J Oncol; 2020 Nov; 57(5):1179-1191. PubMed ID: 32901840
[TBL] [Abstract][Full Text] [Related]
6. VEGF-C promotes the development of lymphatics in bone and bone loss.
Hominick D; Silva A; Khurana N; Liu Y; Dechow PC; Feng JQ; Pytowski B; Rutkowski JM; Alitalo K; Dellinger MT
Elife; 2018 Apr; 7():. PubMed ID: 29620526
[TBL] [Abstract][Full Text] [Related]
7. Mutant LKB1 Confers Enhanced Radiosensitization in Combination with Trametinib in KRAS-Mutant Non-Small Cell Lung Cancer.
Wang Y; Li N; Jiang W; Deng W; Ye R; Xu C; Qiao Y; Sharma A; Zhang M; Hung MC; Lin SH
Clin Cancer Res; 2018 Nov; 24(22):5744-5756. PubMed ID: 30068711
[No Abstract] [Full Text] [Related]
8. Viewpoints on vessels and vanishing bones in Gorham-Stout disease.
Dellinger MT; Garg N; Olsen BR
Bone; 2014 Jun; 63():47-52. PubMed ID: 24583233
[TBL] [Abstract][Full Text] [Related]
9. Reduced expression of semaphorin 3A in osteoclasts causes lymphatic expansion in a Gorham-Stout disease (GSD) mouse model.
Zhang D; Xu H; Qin C; Cai K; Zhang J; Xia X; Bi J; Zhang L; Xing L; Liang Q; Wang W
J Zhejiang Univ Sci B; 2024 Jan; 25(1):38-50. PubMed ID: 38163665
[TBL] [Abstract][Full Text] [Related]
10. Complex Lymphatic Anomalies: Report on a Patient Registry Using the Latest Diagnostic Guidelines.
Andreoti TA; Berg S; Holm A; Angerer M; Oberlin M; Foeldi E; Baumgartner I; Niemeyer CM; Rössler J; Kapp FG
Lymphat Res Biol; 2023 Jun; 21(3):230-243. PubMed ID: 36706428
[No Abstract] [Full Text] [Related]
11. Selective Endothelial Hyperactivation of Oncogenic KRAS Induces Brain Arteriovenous Malformations in Mice.
Park ES; Kim S; Huang S; Yoo JY; Körbelin J; Lee TJ; Kaur B; Dash PK; Chen PR; Kim E
Ann Neurol; 2021 May; 89(5):926-941. PubMed ID: 33675084
[TBL] [Abstract][Full Text] [Related]
12. Gorham-Stout disease and generalized lymphatic anomaly--clinical, radiologic, and histologic differentiation.
Lala S; Mulliken JB; Alomari AI; Fishman SJ; Kozakewich HP; Chaudry G
Skeletal Radiol; 2013 Jul; 42(7):917-24. PubMed ID: 23371338
[TBL] [Abstract][Full Text] [Related]
13. Trametinib downregulates survivin expression in RB1-positive KRAS-mutant lung adenocarcinoma cells.
Sumi T; Hirai S; Yamaguchi M; Tanaka Y; Tada M; Niki T; Takahashi H; Sakuma Y
Biochem Biophys Res Commun; 2018 Jun; 501(1):253-258. PubMed ID: 29727601
[TBL] [Abstract][Full Text] [Related]
14. Zoledronic acid enhances the efficacy of the MEK inhibitor trametinib in KRAS mutant cancers.
Dai X; Xia H; Zhou S; Tang Q; Bi F
Cancer Lett; 2019 Feb; 442():202-212. PubMed ID: 30429107
[TBL] [Abstract][Full Text] [Related]
15. A combinatorial strategy for treating KRAS-mutant lung cancer.
Manchado E; Weissmueller S; Morris JP; Chen CC; Wullenkord R; Lujambio A; de Stanchina E; Poirier JT; Gainor JF; Corcoran RB; Engelman JA; Rudin CM; Rosen N; Lowe SW
Nature; 2016 Jun; 534(7609):647-51. PubMed ID: 27338794
[TBL] [Abstract][Full Text] [Related]
16. Dasatinib sensitises KRAS-mutant cancer cells to mitogen-activated protein kinase kinase inhibitor via inhibition of TAZ activity.
Rao G; Kim IK; Conforti F; Liu J; Zhang YW; Giaccone G
Eur J Cancer; 2018 Aug; 99():37-48. PubMed ID: 29902613
[TBL] [Abstract][Full Text] [Related]
17. Enhancing Therapeutic Efficacy of Oncolytic Herpes Simplex Virus with MEK Inhibitor Trametinib in Some BRAF or KRAS-Mutated Colorectal or Lung Carcinoma Models.
Zhou X; Zhao J; Zhang JV; Wu Y; Wang L; Chen X; Ji D; Zhou GG
Viruses; 2021 Sep; 13(9):. PubMed ID: 34578339
[TBL] [Abstract][Full Text] [Related]
18. Gorham-Stout disease: radiological, histological, and clinical features of 12 cases and review of literature.
Liu Y; Zhong DR; Zhou PR; Lv F; Ma DD; Xia WB; Jiang Y; Wang O; Xing XP; Li M
Clin Rheumatol; 2016 Mar; 35(3):813-23. PubMed ID: 25227772
[TBL] [Abstract][Full Text] [Related]
19. SHP2 Inhibition Overcomes RTK-Mediated Pathway Reactivation in KRAS-Mutant Tumors Treated with MEK Inhibitors.
Lu H; Liu C; Velazquez R; Wang H; Dunkl LM; Kazic-Legueux M; Haberkorn A; Billy E; Manchado E; Brachmann SM; Moody SE; Engelman JA; Hammerman PS; Caponigro G; Mohseni M; Hao HX
Mol Cancer Ther; 2019 Jul; 18(7):1323-1334. PubMed ID: 31068384
[TBL] [Abstract][Full Text] [Related]
20. Trametinib Drives T-cell-Dependent Control of KRAS-Mutated Tumors by Inhibiting Pathological Myelopoiesis.
Allegrezza MJ; Rutkowski MR; Stephen TL; Svoronos N; Perales-Puchalt A; Nguyen JM; Payne KK; Singhal S; Eruslanov EB; Tchou J; Conejo-Garcia JR
Cancer Res; 2016 Nov; 76(21):6253-6265. PubMed ID: 27803104
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
